UY35578A - Síntesis de compuestos de ester y ácido bórico - Google Patents

Síntesis de compuestos de ester y ácido bórico

Info

Publication number
UY35578A
UY35578A UY0001035578A UY35578A UY35578A UY 35578 A UY35578 A UY 35578A UY 0001035578 A UY0001035578 A UY 0001035578A UY 35578 A UY35578 A UY 35578A UY 35578 A UY35578 A UY 35578A
Authority
UY
Uruguay
Prior art keywords
boric acid
ester compounds
synthesis
bortezomib
scale production
Prior art date
Application number
UY0001035578A
Other languages
English (en)
Inventor
Pickersgill Fraser
Bishop John
Koellner Christoph
Jean-Marc Gomez
Geiser Achim
Hett Robert
Ammoscato Vince
Munk Stephen
Lo Young
Fang-Ting Chiu
Vithalanand R Kulkarni
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to UY0001035578A priority Critical patent/UY35578A/es
Publication of UY35578A publication Critical patent/UY35578A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

La invención se refiere a la síntesis de compuestos de éster y ácido bórico. Más particularmente, la invención proporciona procesos sintéticos mejorados para la producción a gran escala de compuestos de éster y ácido bórico, incluyendo el inhibidor de proteasoma peptídico de ácido bórico bortezomib.
UY0001035578A 2004-03-30 2014-05-19 Síntesis de compuestos de ester y ácido bórico UY35578A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY0001035578A UY35578A (es) 2004-03-30 2014-05-19 Síntesis de compuestos de ester y ácido bórico

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30
UY28830A UY28830A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico
UY0001035578A UY35578A (es) 2004-03-30 2014-05-19 Síntesis de compuestos de ester y ácido bórico

Publications (1)

Publication Number Publication Date
UY35578A true UY35578A (es) 2016-01-08

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
UY28830A UY28830A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico
UY34969A UY34969A (es) 2004-03-30 2013-08-07 Síntesis de compuestos de ester y ácido bórico
UY0001035578A UY35578A (es) 2004-03-30 2014-05-19 Síntesis de compuestos de ester y ácido bórico

Family Applications Before (2)

Application Number Title Priority Date Filing Date
UY28830A UY28830A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico
UY34969A UY34969A (es) 2004-03-30 2013-08-07 Síntesis de compuestos de ester y ácido bórico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP2377869B1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN108329337B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2560886C (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK4008721T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (4) ES2899606T3 (es)
FI (1) FI4008721T3 (es)
HK (4) HK1100004A1 (es)
HR (4) HRP20240307T3 (es)
HU (2) HUE056859T2 (es)
IL (3) IL178250A (es)
LT (2) LT4008721T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ550522A (es)
PE (3) PE20142402A1 (es)
PL (4) PL1756121T3 (es)
PT (4) PT4008721T (es)
RS (4) RS51983B (es)
SG (5) SG10201600029PA (es)
SI (4) SI4008721T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
RS51983B (en) 2004-03-30 2012-02-29 Millennium Pharmaceuticals Inc. SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009020448A1 (en) 2007-08-06 2009-02-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
JP2010539183A (ja) * 2007-09-12 2010-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ボルテゾミブおよびその生成のためのプロセス
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2730579A1 (en) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AU2013204889A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
AU2010261710A1 (en) * 2009-06-19 2012-01-19 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
EA035193B1 (ru) 2010-05-18 2020-05-14 Серулин Фарма Инк. Композиции и способы лечения аутоиммунных и других заболеваний
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
WO2012177835A1 (en) 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
CA2860142C (en) 2011-12-22 2020-10-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
RU2015112190A (ru) * 2012-09-11 2016-11-10 Сипла Лимитед Способ получения бортезомиба
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CA2891822A1 (en) 2012-11-16 2014-05-22 Shilpa Medicare Limited Crystalline bortezomib process
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
CA2909519A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
KR102481856B1 (ko) 2014-05-20 2022-12-26 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
WO2018150386A1 (en) 2017-02-17 2018-08-23 Fresenius Kabi Oncology Ltd. An improved process for the preparation of boronic acid esters
BR112019018447A2 (pt) 2017-03-06 2020-04-14 Venatorx Pharmaceuticals Inc formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
CA3074247A1 (en) 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525309A (en) 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1360189A1 (en) * 2001-01-25 2003-11-12 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
WO2003033507A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
RS51983B (en) 2004-03-30 2012-02-29 Millennium Pharmaceuticals Inc. SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
AU2010261710A1 (en) * 2009-06-19 2012-01-19 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation

Also Published As

Publication number Publication date
CN111925385B (zh) 2023-11-21
NO20191065A1 (no) 2006-12-22
JP2010241816A (ja) 2010-10-28
IL178250A0 (en) 2006-12-31
NL1028639A1 (nl) 2005-10-20
UY34969A (es) 2015-02-27
CN111925385A (zh) 2020-11-13
DK3385267T3 (da) 2021-11-01
UA90108C2 (uk) 2010-04-12
US20050240047A1 (en) 2005-10-27
SI1756121T1 (sl) 2012-03-30
US20190112334A1 (en) 2019-04-18
EP2377869B1 (en) 2014-01-29
SG182999A1 (en) 2012-08-30
NO20161350A1 (no) 2006-12-22
HRP20140339T1 (hr) 2014-05-09
SI4008721T1 (sl) 2024-05-31
EP4008721A1 (en) 2022-06-08
EP2377868A1 (en) 2011-10-19
HRP20240307T3 (hr) 2024-05-10
US10000529B2 (en) 2018-06-19
NO343966B1 (no) 2019-07-29
ES2899606T3 (es) 2022-03-14
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
HUE065769T2 (hu) 2024-06-28
CA2560886A1 (en) 2005-10-20
DOP2011000293A (es) 2011-12-15
HK1164320A1 (en) 2012-10-19
EP3385267A1 (en) 2018-10-10
PE20142402A1 (es) 2015-02-04
RS65253B1 (sr) 2024-03-29
BRPI0509587A (pt) 2007-09-25
SG182998A1 (en) 2012-08-30
CN108329337A (zh) 2018-07-27
PE20060162A1 (es) 2006-04-07
EP1756121B1 (en) 2011-08-24
CA2738706C (en) 2014-10-14
CN1960996B (zh) 2016-04-20
MX367324B (es) 2019-08-15
NZ586824A (en) 2012-03-30
WO2005097809A2 (en) 2005-10-20
US20210171574A1 (en) 2021-06-10
LT4008721T (lt) 2024-03-25
NO344610B1 (no) 2020-02-10
HRP20110846T1 (hr) 2011-12-31
KR100939598B1 (ko) 2010-02-01
JP6193960B2 (ja) 2017-09-06
SI2377869T1 (sl) 2014-05-30
ATE521612T1 (de) 2011-09-15
IL219853A (en) 2015-05-31
IL219853A0 (en) 2012-06-28
CN1960996A (zh) 2007-05-09
CA2859119A1 (en) 2005-10-20
EA012927B1 (ru) 2010-02-26
EP1756121A2 (en) 2007-02-28
PT1756121E (pt) 2011-11-30
NL1033190C2 (nl) 2007-11-27
SI3385267T1 (sl) 2022-04-29
NO20171939A1 (no) 2006-12-22
LT3385267T (lt) 2021-11-10
CY1112053T1 (el) 2015-11-04
US20100174072A1 (en) 2010-07-08
SG151322A1 (en) 2009-04-30
EP3385267B1 (en) 2021-09-29
NZ598172A (en) 2013-08-30
EA200601795A1 (ru) 2007-04-27
ZA200608689B (en) 2007-09-26
JP5894952B2 (ja) 2016-03-30
ES2457593T3 (es) 2014-04-28
CL2014002252A1 (es) 2014-12-05
PT3385267T (pt) 2021-11-23
ECSP066960A (es) 2006-12-20
NO20064893L (no) 2006-12-22
NL1033189A1 (nl) 2007-10-22
AR097310A2 (es) 2016-03-02
IL219856A0 (en) 2012-06-28
NL1033189C2 (nl) 2008-08-14
US20180044377A1 (en) 2018-02-15
US7714159B2 (en) 2010-05-11
US20200157143A1 (en) 2020-05-21
FI4008721T3 (fi) 2024-03-19
US8283467B2 (en) 2012-10-09
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
NZ550522A (en) 2010-08-27
PT2377869E (pt) 2014-04-15
HK1257298A1 (zh) 2019-10-18
PL4008721T3 (pl) 2024-05-13
HUE056859T2 (hu) 2022-03-28
KR20070007873A (ko) 2007-01-16
US20190330270A1 (en) 2019-10-31
ME01975B (me) 2015-05-20
HK1246300A1 (zh) 2018-09-07
PL1756121T3 (pl) 2012-02-29
US20180265546A1 (en) 2018-09-20
TW200616646A (en) 2006-06-01
NO338905B1 (no) 2016-10-31
SG10201600029PA (en) 2016-02-26
CN103396427B (zh) 2018-04-13
MY145427A (en) 2012-02-15
DK2377869T3 (da) 2014-04-14
EP2377869A1 (en) 2011-10-19
ES2974758T3 (es) 2024-07-01
EP4008721B1 (en) 2024-01-03
US20160362449A1 (en) 2016-12-15
JP4558039B2 (ja) 2010-10-06
US20210395301A1 (en) 2021-12-23
TWI386212B (zh) 2013-02-21
ES2371652T3 (es) 2012-01-05
JP2016056180A (ja) 2016-04-21
CN107474062A (zh) 2017-12-15
RS53259B (en) 2014-08-29
CL2010000350A1 (es) 2011-01-28
US20200369722A1 (en) 2020-11-26
PT4008721T (pt) 2024-03-21
PL2377869T3 (pl) 2014-07-31
DK1756121T3 (da) 2012-01-09
PL3385267T3 (pl) 2022-02-14
US20150038706A1 (en) 2015-02-05
AU2005230930A1 (en) 2005-10-20
CA2560886C (en) 2014-08-12
AR097309A2 (es) 2016-03-02
CY1124753T1 (el) 2022-07-22
PE20110075A1 (es) 2011-02-17
AR049374A1 (es) 2006-07-26
WO2005097809A3 (en) 2006-02-16
US20220204558A1 (en) 2022-06-30
SG10201800972PA (en) 2018-03-28
JP2007530687A (ja) 2007-11-01
UY28830A1 (es) 2005-09-30
US9862745B2 (en) 2018-01-09
NL1033190A1 (nl) 2007-04-23
HRP20212002T1 (hr) 2022-04-01
IL219856A (en) 2015-05-31
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
AU2005230930B2 (en) 2011-09-29
HK1100004A1 (en) 2007-08-31
DK4008721T3 (da) 2024-03-25
RS62738B1 (sr) 2022-01-31
CY1115336T1 (el) 2017-01-04
JP2013100378A (ja) 2013-05-23
CN108329337B (zh) 2021-06-25
CA2738706A1 (en) 2005-10-20
JP5414625B2 (ja) 2014-02-12

Similar Documents

Publication Publication Date Title
UY35578A (es) Síntesis de compuestos de ester y ácido bórico
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
ECSP077984A (es) Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina
ATE542798T1 (de) Organische verbindungen
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
UA102817C2 (ru) Способ синтеза агомелатина
BRPI0710199A2 (pt) Processo para preparação de inibidores de hiv protease
AR054533A1 (es) Proceso y reactivo magnetico para la separacion de impurezas de los minerales
UA102220C2 (ru) Способ синтеза агомелатина
TW200728310A (en) Process for the preparation of ferri-succinylcasein
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
TW200612959A (en) Method for preparing hydroxamic acids
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
UA106195C2 (ru) Способ синтеза агомелатина
AR057137A1 (es) Compuestos orgánicos
UA102816C2 (ru) Способ синтеза кристаллической формы v агомелатина
AR051386A1 (es) Proceso para compuestos triciclicos que contienen atomos heterogeneos
NO20074880L (no) Proteaseinhibitor forloper syntese
SE0402199D0 (sv) New process I
MX2007012472A (es) (+)-y-(-)-8-alquil-3-(trifluoralquilsulfoniloxi)-8-azabicicl (3.2.1)cot-2-eno.
TW200700417A (en) Novel enantiopure compounds

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210204